Medibact GuidesShop at Medibact

Stacking Module

Ipamorelin Stacking Module

Ipamorelin is the secretagogue half of the canonical GH-axis stack, and the reason it became the default partner is specific: it is reported to be selective for the ghrelin receptor without the cortisol and prolactin effects attributed to older secretagogues. That selectivity is its entire stacking case.

Ipamorelin Guide at MedibactIpamorelin calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Ipamorelin

  • Ipamorelin acts at GHS-R1a. Its complementary partner is a GHRH analog, not another secretagogue.
  • Its selectivity is the point of choosing it. Pairing it with GHRP-2 or GHRP-6 discards that advantage while adding nothing mechanistically.
  • Reported protocols use it fasted, often at bedtime, on the rationale of aligning with the nocturnal GH pulse.
  • No controlled trial has studied Ipamorelin combined with anything.

Combinations in detail

CJC-1295 + Ipamorelin

Selective GHS-R1a secretagogue + GHRH analog
Why it is proposed
Two distinct upstream pathways converging on GH release — the best-constructed pairing in this catalog on mechanism. Ipamorelin supplies the ghrelin-receptor side without the hormonal side effects reported for older secretagogues.
What is reported in practice
Reported in a single subcutaneous administration, commonly at bedtime with no-DAC CJC-1295, in roughly matched microgram amounts.
Cautions specific to this combination
The matched-amount convention is community practice, not a studied ratio. Confirm whether your CJC-1295 is DAC or no-DAC, since that determines whether bedtime timing means anything.

Mod GRF 1-29 + Ipamorelin

Short-acting GHRH analog + secretagogue
Why it is proposed
Functionally the same pairing using the no-DAC GHRH analog explicitly, which removes the DAC ambiguity. Often reported at 1:1 microgram amounts.
What is reported in practice
Reported fasted, frequently at bedtime, with both drawn together.
Cautions specific to this combination
Mod GRF 1-29 is CJC-1295 without DAC — do not add CJC-1295 to this pairing thinking it is a third mechanism.

Sermorelin + Ipamorelin

GHRH analog (shorter-acting) + secretagogue
Why it is proposed
Same two-pathway construction with Sermorelin as the GHRH side. Sermorelin is the closest to native GHRH and has an approved-drug history, which is why it appears in more clinically-supervised settings.
What is reported in practice
Reported as a bedtime pairing; Sermorelin's short half-life means timing matters more than with a DAC compound.
Cautions specific to this combination
Sermorelin's very short duration makes it sensitive to timing errors that a long-acting analog would absorb.

What to avoid, and why

  • Pairing two ghrelin-receptor secretagogues (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) is the same redundancy on the other pathway — same receptor, same downstream pulse. The coherent construction takes one GHRH analog and one secretagogue, not two of either.
  • Adding GHRP-2 or GHRP-6 to Ipamorelin — this trades away the selectivity that was the reason to use Ipamorelin.
  • Stacking three GH-axis compounds expecting three effects; the axis has one output.

Related reading

Tesamorelin + Ipamorelin — Tesamorelin + IpamorelinCJC-1295 + Ipamorelin — CJC-1295 + IpamorelinThe Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.